ProCE Banner Activity

Near Future Directions: Promising Agents and Combinations Under Investigation

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on CLL to review promising agents and combination therapies currently under investigation in CLL.

Released: December 05, 2019

Expiration: December 03, 2020

No longer available for credit.

Share

Faculty

William G. Wierda

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen Biotech Pharmacyclics

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has disclosed that he has received consulting fees from Genzyme and funds for research support from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, GlaxoSmithKline/Novartis, Janssen, Juno, Karyopharm, Kite, Loxo, Miragen, Oncternal, Pharmacyclics, Sunesis, and Xencor.